Roche lands EU Kadcyla approval, ducks EMA criticism

Share this article:

Roche is riding a wave of good news. The company announced Wednesday that the EU greenlighted Kadcyla for HER2-positive breast cancer. The US approved the drug this year, but the OK was accompanied by questions about its viability. The so-called “super Herceptin” was expected to cost around $94,000 for a standard course of treatment, and the approval overlapped just as a pricing standoff between Memorial Sloan-Kettering and Sanofi ended with the drugmaker yielding on price.

The company is also breathing easy-ish because the European Medicines Agency decided that the firm's failure to reveal 80,000 adverse-events reports was no big deal. FiercePharma reports that Roche says the number of unreported AEs was really 23,000 and the EMA says these incidents were not associated with any negative outcomes.

Share this article:

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.